Visionary Asset Management Raised Its Stake in Gilead Sciences (GILD) by $2.79 Million; Charles River Laboratories (CRL) Holding Has Raised by Eagle Boston Investment Management Inc

April 25, 2018 - By Marie Mckinney

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Visionary Asset Management Inc increased its stake in Gilead Sciences Inc (GILD) by 1457.63% based on its latest 2017Q4 regulatory filing with the SEC. Visionary Asset Management Inc bought 39,356 shares as the company’s stock rose 1.93% while stock markets declined. The institutional investor held 42,056 shares of the health care company at the end of 2017Q4, valued at $3.01M, up from 2,700 at the end of the previous reported quarter. Visionary Asset Management Inc who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $95.46 billion market cap company. The stock increased 0.67% or $0.49 during the last trading session, reaching $73.21. About 2.85 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 9.79% since April 25, 2017 and is uptrending. It has underperformed by 1.76% the S&P500.

Eagle Boston Investment Management Inc increased its stake in Charles River Laboratories (CRL) by 5.65% based on its latest 2017Q4 regulatory filing with the SEC. Eagle Boston Investment Management Inc bought 4,884 shares as the company’s stock declined 1.14% with the market. The institutional investor held 91,302 shares of the health care company at the end of 2017Q4, valued at $9.99 million, up from 86,418 at the end of the previous reported quarter. Eagle Boston Investment Management Inc who had been investing in Charles River Laboratories for a number of months, seems to be bullish on the $5.03 billion market cap company. The stock decreased 0.29% or $0.3 during the last trading session, reaching $104.91. About 99,748 shares traded. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 21.28% since April 25, 2017 and is uptrending. It has outperformed by 9.73% the S&P500.

Among 20 analysts covering Charles River Laboratories (NYSE:CRL), 8 have Buy rating, 1 Sell and 11 Hold. Therefore 40% are positive. Charles River Laboratories had 49 analyst reports since August 3, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Hold” rating and $110.0 target in Thursday, November 2 report. The rating was maintained by Jefferies on Thursday, June 29 with “Buy”. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Market Perform” rating by Wells Fargo on Monday, October 12. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) earned “Neutral” rating by Goldman Sachs on Friday, December 16. On Thursday, November 16 the stock rating was maintained by SunTrust with “Buy”. The rating was maintained by Credit Suisse on Monday, October 16 with “Hold”. The rating was upgraded by Evercore to “Buy” on Wednesday, January 4. The stock of Charles River Laboratories International, Inc. (NYSE:CRL) has “Buy” rating given on Tuesday, June 13 by Jefferies. Robert W. Baird maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Friday, January 8. Robert W. Baird has “Outperform” rating and $92 target. As per Tuesday, February 13, the company rating was maintained by RBC Capital Markets.

Eagle Boston Investment Management Inc, which manages about $1.88B and $1.00 billion US Long portfolio, decreased its stake in Columbus Mckinnon Corp/Ny (NASDAQ:CMCO) by 78,183 shares to 290,893 shares, valued at $11.63M in 2017Q4, according to the filing. It also reduced its holding in Advanced Energy Industries (NASDAQ:AEIS) by 46,697 shares in the quarter, leaving it with 144,121 shares, and cut its stake in Solar Capital Ltd (NASDAQ:SLRC).

Investors sentiment decreased to 1.08 in Q4 2017. Its down 0.38, from 1.46 in 2017Q3. It turned negative, as 35 investors sold CRL shares while 98 reduced holdings. 39 funds opened positions while 104 raised stakes. 44.57 million shares or 0.83% less from 44.95 million shares in 2017Q3 were reported. Hodges accumulated 51,961 shares. Teachers Retirement System Of The State Of Kentucky holds 0.01% or 10,630 shares in its portfolio. Copper Rock Cap Prtn Ltd Com reported 2.08% in Charles River Laboratories International, Inc. (NYSE:CRL). Clark Capital Mngmt Grp invested 0.03% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Rothschild Asset has invested 0.29% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). Goldman Sachs Group Inc invested in 0.03% or 1.01M shares. Raymond James & owns 4,848 shares or 0% of their US portfolio. State Street accumulated 0.01% or 1.30M shares. Teacher Retirement Of Texas reported 0.01% stake. Profund Advsrs Ltd reported 22,255 shares. Moreover, Gamco Invsts Et Al has 0% invested in Charles River Laboratories International, Inc. (NYSE:CRL). Van Berkom Assocs holds 589,637 shares or 2.1% of its portfolio. Pnc Fincl Services Group holds 0% or 24,111 shares. Brown Advisory holds 0.23% or 654,054 shares in its portfolio. Utah Retirement reported 8,797 shares or 0.02% of all its holdings.

Since January 2, 2018, it had 0 buys, and 21 insider sales for $10.85 million activity. $4,945 worth of stock was sold by FOSTER JAMES C on Thursday, February 15. Smith David Ross had sold 100 shares worth $10,843 on Wednesday, February 28. $890,100 worth of stock was sold by MILNE GEORGE M JR on Friday, March 9. $1.08 million worth of Charles River Laboratories International, Inc. (NYSE:CRL) was sold by Girshick Birgit on Tuesday, March 6. CHUBB STEPHEN D sold 2,872 shares worth $312,172.

Since January 2, 2018, it had 0 insider buys, and 18 selling transactions for $39.95 million activity. Cogan John Francis sold $437,588 worth of stock. MARTIN JOHN C sold 50,000 shares worth $3.66M. $1.11M worth of stock was sold by Alton Gregg H on Tuesday, January 2. 5,000 shares were sold by Washington Robin L, worth $401,566 on Wednesday, February 21. On Friday, February 9 WILSON GAYLE E sold $4.68 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 60,000 shares.

Investors sentiment decreased to 0.8 in Q4 2017. Its down 0.23, from 1.03 in 2017Q3. It is negative, as 95 investors sold GILD shares while 545 reduced holdings. 104 funds opened positions while 411 raised stakes. 972.68 million shares or 1.57% more from 957.62 million shares in 2017Q3 were reported. Private Ocean Limited Liability Company holds 0.04% or 1,049 shares in its portfolio. Connecticut-based Fairfield Bush And has invested 0.11% in Gilead Sciences, Inc. (NASDAQ:GILD). Fort LP reported 278,035 shares. Tiger Management Ltd Liability has 0.43% invested in Gilead Sciences, Inc. (NASDAQ:GILD). Curbstone Financial Management owns 11,585 shares or 0.46% of their US portfolio. Tiaa Cref Investment Management Ltd Liability Corporation has invested 0.26% in Gilead Sciences, Inc. (NASDAQ:GILD). Virtu Fin Limited Liability Corp accumulated 35,203 shares. Lafleur Godfrey Ltd Liability Corporation holds 1.12% in Gilead Sciences, Inc. (NASDAQ:GILD) or 63,632 shares. Field Main Savings Bank accumulated 3,650 shares or 0.25% of the stock. Korea Inv owns 1.29 million shares for 0.42% of their portfolio. Strs Ohio, Ohio-based fund reported 1.36M shares. Patten Grp Incorporated reported 330 shares stake. Supplemental Annuity Collective Trust Of Nj invested in 17,000 shares. The California-based Schwab Charles Mgmt has invested 0.29% in Gilead Sciences, Inc. (NASDAQ:GILD). Waverton Inv Management reported 10,525 shares or 0.04% of all its holdings.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: